spacer
home > ict > autumn 2020 > covid-19 exposes untapped potential in the eu’s clinical trial industry
PUBLICATIONS
International Clinical Trials

COVID-19 Exposes Untapped Potential in the EU’s Clinical Trial Industry

The COVID-19 pandemic, and sudden quarantine, affected every industry in the EU, and the clinical trial industry was no exception. In fact, early findings revealed that 70% of research in the EU was impacted in some way as a direct result of COVID-19 (1).

The pharmaceutical industry is infamous for lagging behind when it comes to adapting new technologies; in order to continue studies in the sudden pandemic, the need to introduce technology became paramount. Studies that absolutely had to continue did, but in some cases changed to remote monitoring and telemedicine visits. This not only affected the patients, but it required rapid adaptation and new strategic plans from the sites to keep trials on track.

Sites have always held the key to trial success, but this pandemic has highlighted not only how vital they are to research, but the importance of keeping them satisfied, and not delaying the resources needed to stay in practice. COVID-19 has proven to be a terrible virus that the world is still trying to contain. This places sponsors in a unique position to use this time to not just maintain positive relationships with sites, but improve them.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Relationship Director, Angela La Ronde strives to ensure Greenphire’s solutions and services continue to exceed client needs and drive innovation in the market. Angela has over 15 years of industry experience engaging with clients and technology to improve the clinical trial experience for all stakeholders.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Grupo NotreDame Intermédica (GNDI) of Brazil enhances patient care and improves patient access to leading-edge medications by joining Clinerion’s global network of hospital partners on Patient Network Explorer

Grupo NotreDame Intermédica (GNDI) is the largest healthcare operator in Brazil, with 6.4 million members. Founded in 1968, it is a pioneer in preventive medicine. GNDI has a wide offer, comprising 29 hospitals, 88 clinical centers, 23 autonomous emergency rooms, 15 preventive medicine centers and 2 health centers exclusively dedicated to the over-fifties.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement